Rezolute, Inc. is a late-stage rare disease company making significant strides in addressing critical health challenges associated with hypoglycemia and diabetic macular edema through its innovative therapeutic candidates, Ersodetug and RZ402.

Rezolute Inc. has navigated a financial rollercoaster with a $90 million stock offering, while making promising progress in its clinical trials for its lead asset Ersodetug, a treatment for hypoglycemia caused by hyperinsulinism.